- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00946374
Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma (HD-MCL2003)
July 24, 2009 updated by: Heidelberg University
A Prospective Phase II Trial on R-CHOP Followed by High-dose BEAM and Autologous SCT and HLA-identical Allogenic SCT After Dose-reduced Conditioning in Patients Age < 55 Years With Primary Mantle-Cell-Lymphoma
The purpose of this study is to improve the overall survival of Mantle-Cell-Lymphoma (MCL) by a new concept of treatment with primary curative intention consisting of six courses of immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (SCT) and HLA-identical allogenic SCT after a dose-reduced conditioning regimen of total body irradiation (TBI) with 2 Gy and Fludarabine in younger patients with primary Mantle-Cell-Lymphoma
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
With a median overall survival of approximately 3 years, MCL has the poorest prognosis of all NHL entities.
No potentially curative therapy has been established yet as even more intensive therapies including high-dose chemotherapy plus autologous SCT show only moderate improvement of the prognosis of MCL.
Allogenic SCT seems to have an immunological mechanism of action in NHL, which is commonly known as Graft-versus-Lymphoma effect.
This trial´s purpose is to improve the overall survival in patients younger than 55 years with primary MCL by sequentially combining autologous SCT and allogenic SCT after the application of 6 courses of immunochemotherapy and high-dose chemotherapy.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Markus Munder, M. D.
- Phone Number: 32370 0049 6221 56
- Email: markus.munder@med.uni-heidelberg.de
Study Locations
-
-
-
Heidelberg, Germany, 69120
- Recruiting
- University Hospital
-
Contact:
- Markus Munder, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- First diagnosis of Mantle-Cell-Lymphoma without any previous therapies except for pre-phase treatment consisting of steroids
- Age 18 to 55 years
- Confirmed CD20-expression on lymphocytes
- Effective methods of contraception and negative pregnancy test
- Sufficient compliance
- Written patient´s informed consent
Exclusion Criteria:
- Manifest cardiac insufficiency, not compensated
- Congestive Cardiomyopathy
- Chronic pulmonary disease including hypoxemia
- Severe hypertension, not condensable with drugs
- Severe diabetes mellitus not condensable with drugs
- Renal Insufficiency ( serum creatinin > 2,0 mg/dl, other than Lymphoma related)
- Liver impairment ( Transaminases value more than 3 x upper normal value or Bilirubin > 2,0 mg/dl, other than Lymphoma related)
- HIV-Infection
- Active Hepatitis B-Infection if continuous virostatic treatment is not possible
- Active Hepatitis C-Infection
- Clinical signs of cerebrovascular insufficiency or cerebral damages
- Pregnancy, lactation or inadequate contraception in women of childbearing age
- Severe psychiatric disorders
- Transplantation in the past
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy: ORR, OS, EFS
Time Frame: during treatment and on day 720 after allogenic SCT
|
during treatment and on day 720 after allogenic SCT
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxicity according to WHO-Grading
Time Frame: During treatment and until follow-up
|
During treatment and until follow-up
|
GvL-effect after allogenic SCT
Time Frame: Allogenic SCT until day 720 after transplantation
|
Allogenic SCT until day 720 after transplantation
|
Comparison of OS between patients completing the protocol and patients not receiving allogenic SCT
Time Frame: First diagnosis of MCL until day 720 after transplantation
|
First diagnosis of MCL until day 720 after transplantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anthony D. Ho, Ph.D., Prof., director of department
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2004
Primary Completion (Anticipated)
December 1, 2010
Study Completion (Anticipated)
June 1, 2011
Study Registration Dates
First Submitted
July 24, 2009
First Submitted That Met QC Criteria
July 24, 2009
First Posted (Estimate)
July 27, 2009
Study Record Updates
Last Update Posted (Estimate)
July 27, 2009
Last Update Submitted That Met QC Criteria
July 24, 2009
Last Verified
July 1, 2009
More Information
Terms related to this study
Keywords
- NHL
- TBI
- MCL
- Unrelated donor
- CHOP
- R-CHOP
- Total Body Irradiation
- Autologous stem cell transplantation
- BEAM
- ASCT
- Immunochemotherapy
- Allogenic stem cell transplantation
- Mantle-Cell-Lymphoma
- Non Hodgkin´s Lymphoma
- High-dose chemotherapy
- HD-BEAM
- Reduced conditioning regimen
- Sibling donor
- ABSCT
- Fludarabine+TBI
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Mantle-Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Calcineurin Inhibitors
- Doxorubicin
- Cyclosporine
Other Study ID Numbers
- L-149/2003
- BfArM: A-7140-00-37/4021157
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mantle-Cell Lymphoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Janssen Scientific Affairs, LLCActive, not recruitingStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma | Stage II Contiguous Mantle Cell Lymphoma | Stage II Non-Contiguous Mantle Cell LymphomaUnited States
-
Burzynski Research InstituteWithdrawnRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell LymphomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Ann Arbor Stage I Mantle Cell Lymphoma | Ann Arbor Stage II Mantle Cell Lymphoma | Ann Arbor Stage III Mantle Cell Lymphoma | Ann Arbor Stage IV Mantle Cell LymphomaUnited States
-
BeiGeneRecruitingMantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina, Puerto Rico
-
BeiGeneCompletedRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaChina
-
Fondazione Italiana Linfomi - ETSRecruitingRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaItaly
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell LymphomaUnited States
Clinical Trials on Immunochemotherapy
-
Shanghai Zhongshan HospitalCompleted
-
Hoffmann-La RocheCompletedNon-Hodgkin's LymphomaColombia, Mexico
-
Jiang FengRecruiting
-
Fondazione Italiana Linfomi - ETSRecruiting
-
University of AarhusMundipharma Pte Ltd.; Roche Pharma AG; Schering-Plough; Nordic Cancer UnionCompletedCentral Nervous System LymphomaDenmark
-
Henan Cancer HospitalRecruitingEsophageal Cancer | Surgery | Survival | Neoadjuvant TreatmentChina
-
IRCCS Policlinico S. MatteoCompleted
-
TheracosCompletedType 2 Diabetes MellitusUnited States, Canada, Czechia, Denmark, Korea, Republic of, Mexico, Netherlands, Poland, Russian Federation, Taiwan
-
Centre hospitalier de l'Université de Montréal...University of British Columbia; McGill University; University of Alberta; McMaster... and other collaboratorsRecruitingCarotid Stenosis | Carotid Artery Diseases | Stroke, AcuteCanada
-
Cancer Institute and Hospital, Chinese Academy...RecruitingNon-Small Cell Lung CancerChina